A coordinate-based meta-analysis pooled data from 147 voxel-based morphometry studies and identified shared gray matter volume (GMV) reductions across three psychiatric conditions. The analysis involved schizophrenia, major depressive disorder, and alcohol use disorder, totaling 13,041 participants according to the authors. Investigators reported overlapping GMV loss in the ventromedial prefrontal cortex, ventral anterior cingulate cortex, insula and superior temporal gyrus. These regions are traditionally implicated in social cognition; the study team observed that their structural deficits were common across diagnostic boundaries, not confined to a single disorder.
The group-level maps emerged from a random-effects Seed-based d Mapping with Permutation of Subject Images (SDM-PSI) pipeline. Statistical inference used permutation testing with a threshold of p < .0025 and a cluster extent minimum of 10 voxels, as reported by the authors. Short statements of effect would understate this work: the meta-analysis aimed to characterize transdiagnostic neuroanatomical substrates that could relate to shared symptoms such as social withdrawal and anhedonia.
Alongside the shared loci, the study team identified distinct volumetric abnormalities that varied by diagnosis. The source states there were both common and separate GMV abnormalities in the three disorders, although the abstract does not enumerate every disorder-specific cluster or its anatomical coordinates. Readers should note that the included studies were heterogeneous in number across disorders—90 schizophrenia studies, 44 major depressive disorder studies and 13 alcohol use disorder studies—so the density of evidence differs by condition and may influence sensitivity to detect disorder-specific effects.
The meta-analytic approach contrasted patients with healthy controls on a whole-brain basis. Authors reported that shared deficits mapped onto networks associated with social processing and theory-of-mind functions; the cohort-level patterns therefore reflect both localized GMV loss and broader network involvement. The source did not provide details on medication status, illness duration, or comorbidity breakdowns in the abstract, so disorder-specific interpretations beyond those reported would require consulting the full dataset on the authors' OSF repository.
The study team performed characterization analyses linking the shared structural deficits to neurotransmitter and genetic systems. Data indicated involvement of dopaminergic and serotonergic neurotransmitter systems in the regions showing convergent GMV reductions. Authors also reported associated genetic annotations for those loci. These annotations suggest potential molecular pathways that could underlie overlapping clinical features—anhedonia and social withdrawal—across the three diagnoses. The abstract, however, does not provide the specific genes or receptor subtypes implicated, nor does it list effect sizes for those associations; the source did not report such granularity in the abstract.
Investigators conducted a comprehensive literature search across three databases—PubMed, Web of Science and PsycInfo—from January 2000 to March 2024, supplemented by review-article searches. The pre-registered protocol is available on OSF (link provided in the source). Inclusion required English-language whole-brain VBM results comparing patients and healthy controls. Data extraction was performed independently and verified by three contributors. Random-effects SDM-PSI was used to generate statistical brain maps, with permutation testing and a threshold of p < .0025 plus a cluster extent of 10 voxels.
Heterogeneity was assessed using the I2 statistic; publication bias was examined with Egger's regression test. The abstract reports that these evaluations were performed but does not supply the numerical I2 values or the outcome statistics from Egger's tests. The pooled literature comprised 147 studies with an uneven distribution across disorders: 90 schizophrenia, 44 MDD, and 13 AUD studies. The meta-analysis therefore capitalized on a large aggregate sample while drawing attention to the relative paucity of AUD studies within the VBM literature included here.
The authors declared no competing interests and made their data available on OSF. The source reports several methodological features but omits granular detail in the abstract: specific disorder-level cluster coordinates, numerical heterogeneity estimates (I2), and the exact results of publication-bias testing are not provided in the abstract. The marked imbalance in study counts across diagnoses—far more schizophrenia studies than alcohol use disorder studies—is a documented feature of the included literature and may limit sensitivity to detect AUD-specific patterns. The source did not report medication, illness-duration, or comorbidity subgroup results in the abstract; those remain open questions for readers who consult the full data.
Unresolved clinical questions remain explicit in the authors' reporting: which specific genes and receptor subtypes drive the dopaminergic and serotonergic annotations, how medication or illness chronicity modulate the shared GMV reductions, and whether prospective, harmonized imaging studies can replicate these transdiagnostic loci. The abstract does not provide timelines or regulatory milestones for translational follow-up; further work will require targeted study designs and detailed subgroup reporting to answer these outstanding items.